Small molecule · Inhibitor · developed by Quantum Biopharma
FSD-201 is an orally bioavailable, ultra-micronized formulation of palmitoyl ethylamine (PEA), a fatty acid amide. It inhibits mast cell activation and migration, and reduces the release of pro-inflammatory mediators from activated mast cells. It is studied in mast cell activation syndrome and idiopathic mast cell activation disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05652907 | Phase 2 | Mast Cell Activation Syndrome | Terminated | QNTM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mast Cell Activation Disorder IdiopathicMast Cell Activation Syndrome
Updated Oct 3, 2026. Something wrong or missing? Report it on the QNTM page.
See QNTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
QNTM catalysts and pipeline →